@article{5112874830c2487eb526d2e2fe952045,
title = "The nature, assessment, and treatment of obsessive-compulsive disorder",
abstract = "Obsessive-compulsive disorder (OCD) is an anxiety disorder that affects between 1% to 2% of individuals and causes considerable impairment and disability. Although. 50% of individuals experience symptom onset in childhood, symptoms can continue to develop throughout adulthood. Accurate and timely assessment of clinical presentation is critical to limitimpairment and improve prognosis. Presently, there are 2 empirically supported treatments available for OCD in children and adults, namely cognitive-behavioral therapy and pharmacotherapy with serotonin reuptake inhibitors. This article provides an introduction to the phenomenology, etiology, and clinical course of OCD. Assessment practices used to evaluate symptom severity are described, and evidence-based treatment options are reviewed, with appropriate distinctions drawn between children and adults. Finally, recommendations for assessment and treatment practices for OCD are explicated.",
keywords = "Assessment, Etiology, Obsessive-compulsive disorder, Phenomenology, Treatment",
author = "McGuire, {Joseph F.} and Lewin, {Adam B.} and Betty Horng and Murphy, {Tanya K.} and Storch, {Eric A.}",
note = "Funding Information: Adam B. Lewin, PhD is a consultant for Otsuka Pharmaceuticals and Prophase, Inc. Tanya K. Murphy, MD receives research funding from the National Institutes of Health, Centers for Disease Control and Prevention, National Alliance for Research on Schizophrenia and Affective Disorders, Otsuka Pharmaceuticals, Forest Pharmaceuticals, Ortho-McNeil Janssen Pharmaceuticals, Shire Pharmaceuticals, and Indevus Pharmaceuticals. She receives travel support from the Tourette Syndrome Association and honorarium from the Arizona Psychiatric Association. Eric A. Storch, PhD has received grant funding in the last 3 years from the National Institutes of Health, All Children{\textquoteright}s Hospital Research Foundation, the Centers for Disease Control and Prevention, the National Alliance for Research on Schizophrenia and Affective Disorders, the International OCD Foundation, Tourette Syndrome Association, Janssen Pharmaceuticals, and the Foundation for Research on Prader-Willi Syndrome. He receives textbook honorarium from Springer publishers, the American Psychological Association, and Lawrence Erlbaum. Dr. Storch has been an educational consultant for Rogers Memorial Hospital. He is a consultant for Prophase, Inc. and is on the speakers{\textquoteright} bureau and scientific advisory board for the International OCD Foundation. He receives research support from All Children{\textquoteright}s Hospital Guild Endowed Chair. Joseph F. McGuire, BA and Betty Horng, PhD disclose no conflicts of interest.",
year = "2012",
month = jan,
doi = "10.3810/pgm.2012.01.2528",
language = "English (US)",
volume = "124",
pages = "152--165",
journal = "Postgraduate medicine",
issn = "0032-5481",
publisher = "Medquest Communications LLC",
number = "1",
}